-
Gland Pharma
2,969.85 3,039.00(%) -
Power Fin.Corpn.
357.70 486.45(%) -
IFCI
107.45 107.45(%) -
Shriram Finance
1,036.40 584.25(%) -
Tata Technolog.
796.45 507.50(%) -
ESDS Software
895.55 895.55(%) -
Lenskart Solut.
694.75 694.75(%) -
Netweb Technol.
5,170.00 2,514.75(%) -
Lumino Inds
122.00 122.00(%) -
Kesar India
1,180.00 1,341.00(%) -
Multi Comm. Exc.
3,287.00 3,479.80(%) -
Tejas Networks
623.90 644.75(%) -
RBL Bank
417.00 417.00(%) -
ICICI AMC
2,960.00 2,528.90(%) -
Polycab India
8,254.00 6,660.50(%) -
New India Assura
234.60 234.60(%) -
Wockhardt
2,107.95 2,420.00(%) -
Angel One
308.20 360.20(%) -
Jindal Worldwide
57.06 57.06(%) -
Lalithaa Jewel
308.55 308.55(%)
- Overview
- Key Ratios
- Financials
- Shareholding
- Company Info
- Peer Comparison
- Overview
- Key Ratios
- Financials
- Shareholding
- Company Info
- Peer Comparison
Jenburkt Pharmaceuticals Ltd Pharmaceuticals - Indian - Formulations
- Indian Private
- BSE Code : 4394.0
- ISIN : INE354A01013
-
Today’s Low
1,030.00 -
Today’s High
1,045.00
-
Open
1,036.20 -
Perv Close
1,031.50 -
52W Low
1,010.00 -
52W High
1,073.90
Key Indicators
-
P/E(TTM)
12.78
-
Mar.Cap (₹Cr.)
458.45
-
Div & Yield %
2.00
-
Book Value(₹)
446.47
-
Debt-Equity Ratio
0.71
-
AGM Date
04-Sep-2026
-
EPS
80.96
-
P/E Ratio
12.78
Financials Ratios
-
Debt-Equity Ratio
-
-
Mar.Cap (₹Cr.)
458.45
-
RONW (%)
-
-
ROCE (%)
-
Score Board
-
Equity (₹ in Cr.)
4.41
-
BV (₹)
446.50
-
Sales( ₹ in Cr.)
168.74
-
NP (in Cr.)
37.34
-
NP Var(%)
20.0
-
Div%
207.0
-
CPS (₹)
91.70
-
EPS (₹)
84.60
-
Traded Value (₹ in Lakhs)
456.51
-
52 Week High
1,073.90
-
52 Week Low
1,010.00
-
Price BSE
1034.0
-
Price NSE
1,039.00
-
Market Capital( in Cr.)
456.51
-
P/C Ratio
11.30
-
P/E Ratio
12.20
-
Price Vs.BV
84.60
-
06-May-2026( 09:44)
Corporate News - Board... - Jenburkt Pharmaceuticals annou...
-
06-May-2026( 09:44)
Corporate News - Jenbu... - Jenburkt Pharmaceuticals annou...
-
06-May-2026( 07:27)
Results - Announcements - Jenbu... - Net profit of Jenburkt Pharmac...
-
29-Apr-2026( 10:06)
Corporate News - Jenbu... - Jenburkt Pharmaceuticals will...
Navigate The Market With Confidence
Your all-in-one destination for expert investment guidance and streamlined portfolio management solutions
Financials
All Values are in (₹Cr)| Particulars(INCOME) | 2026 Mar | 2025 Mar | 2024 Mar | 2023 Mar | 2022 Mar | 2021 Mar |
|---|---|---|---|---|---|---|
| INCOME : | ||||||
| Sales Turnover | 168.74 | 151.69 | 141.97 | 136.75 | 123.98 | 109.29 |
| Excise Duty | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Sales | 168.74 | 151.69 | 141.97 | 136.75 | 123.98 | 109.29 |
| Other Income | 10.30 | 6.72 | 4.67 | 5.12 | 4.95 | 4.31 |
| Stock Adjustments | 4.85 | 0.12 | 0.39 | -1.34 | 2.28 | -3.18 |
| Total Income | 183.89 | 158.53 | 147.03 | 140.53 | 131.21 | 110.42 |
| EXPENDITURE : | ||||||
| Raw Materials | 37.17 | 29.77 | 30.80 | 31.67 | 33.72 | 26.91 |
| Power and Fuel Cost | 0.76 | 0.71 | 0.75 | 0.76 | 0.61 | 0.50 |
| Employee Cost | 49.88 | 45.54 | 42.49 | 38.81 | 36.49 | 32.38 |
| Other Manufacturing Expenses | 4.95 | 4.30 | 3.58 | 4.28 | 3.85 | 2.50 |
| Selling and Administration Expenses | 36.44 | 30.27 | 31.04 | 29.03 | 24.32 | 23.03 |
| Miscellaneous Expenses | 4.60 | 0.83 | 0.58 | 0.50 | 0.01 | 0.95 |
| Employee Benefit Expenses | 49.88 | 45.54 | 42.49 | 38.81 | 36.49 | 32.38 |
| Less: Preoperative Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Expenses | 133.80 | 111.41 | 109.24 | 105.05 | 99.01 | 86.26 |
| Operating Profit | 50.09 | 47.11 | 37.79 | 35.49 | 32.20 | 24.15 |
| Interest | 0.46 | 0.45 | 0.27 | 0.37 | 0.43 | 0.47 |
| Gross Profit | 49.63 | 46.66 | 37.52 | 35.12 | 31.77 | 23.68 |
| Depreciation | 3.11 | 2.73 | 2.34 | 2.26 | 1.90 | 2.04 |
| Profit Before Tax | 46.52 | 43.93 | 35.18 | 32.86 | 29.87 | 21.64 |
| Current Tax | 12.64 | 12.08 | 9.72 | 8.48 | 7.28 | 5.53 |
| Fringe Benefit tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Tax | -0.86 | -0.21 | -0.52 | -0.23 | 0.30 | -0.39 |
| Reported Net Profit | 34.74 | 32.06 | 25.98 | 24.61 | 22.30 | 16.50 |
| Extraordinary Items | -2.61 | 1.02 | 0.04 | 0.00 | 0.14 | 0.00 |
| Adjusted Net Profit | 37.35 | 31.04 | 25.94 | 24.61 | 22.16 | 16.50 |
| Adjustment below Net Profit | 0.00 | 0.00 | 0.00 | -14.34 | 0.00 | 0.00 |
| P & L Balance brought forward | 162.34 | 134.12 | 113.11 | 108.53 | 90.91 | 74.41 |
| Statutory Appropriations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Appropriations | 6.91 | 3.84 | 4.96 | 5.69 | 4.68 | 0.00 |
| P & L Balance carried down | 190.17 | 162.34 | 134.12 | 113.10 | 108.53 | 90.91 |
| Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preference Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Equity Dividend (%) | 207.00 | 180.00 | 153.00 | 144.00 | 120.00 | 102.00 |
| Dividend Per Share(Rs) | 20.70 | 18.00 | 15.30 | 14.40 | 12.00 | 10.20 |
| Earnings Per Share-Unit Curr | 78.71 | 72.65 | 58.86 | 55.76 | 48.58 | 35.96 |
| Earnings Per Share(Adj)-Unit Curr | 78.71 | 72.65 | 58.86 | 55.76 | 48.58 | 35.96 |
| Book Value | 446.47 | 389.23 | 328.42 | 277.32 | 255.77 | 214.55 |
| Book Value(Adj)-Unit Curr | 446.47 | 389.23 | 328.42 | 277.32 | 255.77 | 214.55 |
